Skip to content

Establishment of precise drug screening and clinical efficacy evaluation system for solid tumor based on SZC primary culture technology

Establishment of precise drug screening and clinical efficacy evaluation system for solid tumor based on SZC primary culture technology

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200065800
Enrollment
Unknown
Registered
2022-11-15
Start date
2022-11-22
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung cancer

Interventions

Experimental group:Primary cells were cultured from tumor tissues or puncture specimens and tested for drug sensitivity to guide patients taking drugs

Sponsors

Shenzhen People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 69 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-69 years (inclusive), no gender limit; 2. Lung cancer patients with stage III and above, pathological type of which is lung adenocarcinoma; 3. Cancer tissue specimens can be obtained by puncture or operation for primary culture; 4. Subjects must give informed consent to the study prior to the study, voluntarily sign written informed consent, and be willing and able to comply with the study plan's medication, follow-up visits, reviews, and other study procedures.

Exclusion criteria

Exclusion criteria: 1. A history of syphilis, AIDS and other infectious diseases. 2. Patients who do not need medication. 3. Patients whose specimens cannot be cultured in primary culture.

Design outcomes

Primary

MeasureTime frame
SZC drug sensitivity;therapeutic effect evaluation;

Countries

China

Contacts

Public ContactZou Chang

Shenzhen People's Hospital

zou.chang@szhospital.com+86 18617174588

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026